Trials / Completed
CompletedNCT02807233
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
Observational, Multicenter, Cross-sectional, Observational Study to Evaluate the Effectiveness in Routine Clinical Practice of Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) for the Treatment of Acromegaly: SOMACROL Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 115 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness in IGF-1 control of lanreotide Autogel (ATG) 120 mg at extended dosing intervals (EDIs) (\>4 weeks) in subjects with acromegaly in daily clinical practice.
Conditions
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2016-06-21
- Last updated
- 2019-08-05
Locations
39 sites across 2 countries: Portugal, Spain
Source: ClinicalTrials.gov record NCT02807233. Inclusion in this directory is not an endorsement.